OTCMKTS:MLNTQ

Melinta Therapeutics Competitors

$0.11
0.00 (0.00 %)
(As of 04/20/2020)
Add
Compare
Today's Range
$0.11
Now: $0.11
$0.11
50-Day Range
$0.11
MA: $0.11
$0.11
52-Week Range
$0.06
Now: $0.11
$8.60
Volume32,900 shs
Average Volume213,569 shs
Market Capitalization$1.51 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Melinta Therapeutics (OTCMKTS:MLNTQ) Vs. WCUI, IPCIF, BCTXF, FWDG, ISCO, and AMBS

Should you be buying MLNTQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Melinta Therapeutics, including Wellness Center USA (WCUI), Intellipharmaceutics International (IPCIF), BriaCell Therapeutics (BCTXF), FutureWorld (FWDG), International Stem Cell (ISCO), and Amarantus BioScience (AMBS).

Wellness Center USA (OTCMKTS:WCUI) and Melinta Therapeutics (OTCMKTS:MLNTQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Insider & Institutional Ownership

0.1% of Wellness Center USA shares are held by institutional investors. 14.1% of Wellness Center USA shares are held by insiders. Comparatively, 60.3% of Melinta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Wellness Center USA and Melinta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wellness Center USAN/AN/A-1,809.19%
Melinta TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Wellness Center USA and Melinta Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wellness Center USA0000N/A
Melinta Therapeutics0000N/A

Earnings & Valuation

This table compares Wellness Center USA and Melinta Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wellness Center USA$30,000.00190.18$-2,390,000.00N/AN/A
Melinta Therapeutics$96.43 million0.02$-157,190,000.00N/AN/A

Wellness Center USA has higher earnings, but lower revenue than Melinta Therapeutics.

Intellipharmaceutics International (OTCMKTS:IPCIF) and Melinta Therapeutics (OTCMKTS:MLNTQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Earnings & Valuation

This table compares Intellipharmaceutics International and Melinta Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellipharmaceutics International$3.48 million1.36$-8,090,000.00N/AN/A
Melinta Therapeutics$96.43 million0.02$-157,190,000.00N/AN/A

Intellipharmaceutics International has higher earnings, but lower revenue than Melinta Therapeutics.

Profitability

This table compares Intellipharmaceutics International and Melinta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intellipharmaceutics International-232.11%N/A-81.71%
Melinta TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Intellipharmaceutics International and Melinta Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intellipharmaceutics International0000N/A
Melinta Therapeutics0000N/A

Summary

Melinta Therapeutics beats Intellipharmaceutics International on 3 of the 5 factors compared between the two stocks.

BriaCell Therapeutics (OTCMKTS:BCTXF) and Melinta Therapeutics (OTCMKTS:MLNTQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Profitability

This table compares BriaCell Therapeutics and Melinta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BriaCell TherapeuticsN/AN/A-786.77%
Melinta TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares BriaCell Therapeutics and Melinta Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A
Melinta Therapeutics$96.43 million0.02$-157,190,000.00N/AN/A

BriaCell Therapeutics has higher earnings, but lower revenue than Melinta Therapeutics.

Insider and Institutional Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. 60.3% of Melinta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BriaCell Therapeutics and Melinta Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BriaCell Therapeutics0000N/A
Melinta Therapeutics0000N/A

Summary

Melinta Therapeutics beats BriaCell Therapeutics on 3 of the 5 factors compared between the two stocks.

Melinta Therapeutics (OTCMKTS:MLNTQ) and FutureWorld (OTCMKTS:FWDG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Profitability

This table compares Melinta Therapeutics and FutureWorld's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Melinta TherapeuticsN/AN/AN/A
FutureWorldN/AN/AN/A

Earnings & Valuation

This table compares Melinta Therapeutics and FutureWorld's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Melinta Therapeutics$96.43 million0.02$-157,190,000.00N/AN/A
FutureWorldN/AN/AN/AN/AN/A

FutureWorld has lower revenue, but higher earnings than Melinta Therapeutics.

Analyst Ratings

This is a summary of recent ratings for Melinta Therapeutics and FutureWorld, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Melinta Therapeutics0000N/A
FutureWorld0000N/A

Summary

Melinta Therapeutics beats FutureWorld on 1 of the 1 factors compared between the two stocks.

Melinta Therapeutics (OTCMKTS:MLNTQ) and International Stem Cell (OTCMKTS:ISCO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Profitability

This table compares Melinta Therapeutics and International Stem Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Melinta TherapeuticsN/AN/AN/A
International Stem Cell-55.56%N/A-72.21%

Earnings & Valuation

This table compares Melinta Therapeutics and International Stem Cell's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Melinta Therapeutics$96.43 million0.02$-157,190,000.00N/AN/A
International Stem Cell$9.47 million0.48$-4,260,000.00N/AN/A

International Stem Cell has lower revenue, but higher earnings than Melinta Therapeutics.

Analyst Ratings

This is a summary of recent ratings for Melinta Therapeutics and International Stem Cell, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Melinta Therapeutics0000N/A
International Stem Cell0000N/A

Summary

Melinta Therapeutics beats International Stem Cell on 3 of the 5 factors compared between the two stocks.

Amarantus BioScience (OTCMKTS:AMBS) and Melinta Therapeutics (OTCMKTS:MLNTQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Insider & Institutional Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 10.3% of Amarantus BioScience shares are owned by insiders. Comparatively, 60.3% of Melinta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Amarantus BioScience and Melinta Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarantus BioScience0000N/A
Melinta Therapeutics0000N/A

Profitability

This table compares Amarantus BioScience and Melinta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarantus BioScienceN/AN/AN/A
Melinta TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Amarantus BioScience and Melinta Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarantus BioScienceN/AN/AN/AN/AN/A
Melinta Therapeutics$96.43 million0.02$-157,190,000.00N/AN/A

Amarantus BioScience has higher earnings, but lower revenue than Melinta Therapeutics.

Summary

Melinta Therapeutics beats Amarantus BioScience on 2 of the 3 factors compared between the two stocks.


Melinta Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.05flat$5.71 million$30,000.000.00High Trading Volume
Gap Up
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.20flat$4.74 million$3.48 million-1.67
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00flat$4.56 millionN/A0.00Gap Down
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.60flat$4.52 million$9.47 million0.00High Trading Volume
Gap Up
AMBS
Amarantus BioScience
0.0$0.01flat$3.87 millionN/A0.00Increase in Short Interest
Gap Down
AKRXQ
Akorn
0.1$0.03flat$3.60 million$682.43 million-0.01
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.09flat$3.60 million$3.65 million0.00News Coverage
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01flat$3.50 millionN/A0.00Gap Up
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14flat$2.88 millionN/A0.00Gap Down
RSPI
RespireRx Pharmaceuticals
0.5$0.04flat$2.87 millionN/A-0.09Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$2.20 million$20,000.00-0.99Gap Up
IMUCD
ImmunoCellular Therapeutics
0.0$0.51flat$2.14 millionN/A0.00Gap Up
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
NSPX
Inspyr Therapeutics
0.5$0.01flat$1.97 millionN/A0.00Gap Up
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01flat$1.95 million$2 million0.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04flat$1.83 million$530,000.000.00
WWHC
W World
0.8$6.09flat$1.80 millionN/A0.00Increase in Short Interest
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.48flat$1.70 millionN/A0.00Gap Up
Cardax logo
CDXI
Cardax
0.0$2.00flat$1.59 million$710,000.000.00News Coverage
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.30 million$8.73 million0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.24flat$1.27 millionN/A0.00Decrease in Short Interest
Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02flat$1.17 millionN/A0.00
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57Upcoming Earnings
High Trading Volume
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$1.07 millionN/A0.00Increase in Short Interest
Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$978,000.00N/A0.00Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$970,000.00N/A0.00Increase in Short Interest
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08flat$872,000.00$250,000.000.00
PXYN
Praxsyn
0.6$0.00flat$848,000.00N/A0.00Increase in Short Interest
News Coverage
SKVI
Skinvisible
0.7$0.15flat$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
SPHS
Sophiris Bio
0.1$0.02flat$567,000.00N/A0.00Increase in Short Interest
Gap Up
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02flat$506,000.00N/A0.00Gap Up
TRPXD
Therapix Biosciences
0.0$9.00flat$450,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.15flat$396,000.00N/A0.00News Coverage
Gap Up
HSTC
HST Global
0.8$0.07flat$378,000.00N/A0.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01flat$343,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00Gap Up
PZRXQ
PhaseRx
0.2$0.02flat$298,000.00N/A0.00Gap Down
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01flat$244,000.00N/A0.00Gap Down
WDBG
Woodbrook Group
0.0$1.60flat$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.10flat$183,000.00N/A0.00
MetaStat logo
MTST
MetaStat
0.0$0.02flat$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02flat$7,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.03flat$0.00N/A0.00Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.